XML 12 R13.htm IDEA: XBRL DOCUMENT
v3.19.3

Note 6 - Share-based Compensation | 9 Months Ended
--- | ---
Sep. 30, 2019
Notes to Financial Statements |
Share-based Payment Arrangement [Text Block] | NOTE 6 – Share-Based Compensation : In May 2013, the stockholders of the Company approved the 2013 Incentive Stock and Awards Plan (the “2013 Plan”), authorizing the granting of incentive stock options, non-qualified stock options, stock appreciation rights (“SARs”), restricted stock, performance shares and other stock based compensation. A total of 5,000,000 shares of common stock (subject to adjustment for expirations and cancellations of options outstanding from the previous plan) have been reserved for issuance under the 2013 Plan. All options and SARs have been or will be granted with exercise prices at least equal to the fair market value of the shares on the date of grant. At September 30, 2019 , the Company had 3,320,743 shares of common stock available for grant of share-based compensation under the 2013 Plan. Share-based compensation is recorded in selling and administrative expense in the statements of comprehensive income. The following table details the share-based compensation expense by type of award and the total related tax benefit for the periods presented (in thousands):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Stock options and SARs |  | $ | 108 |  |  | $ | 16 |  |  | $ | 286 |  |  | $ | 960 |
Restricted stock |  |  | 215 |  |  |  | 140 |  |  |  | 612 |  |  |  | 404 |
Performance shares(1) |  |  | (358 | ) |  |  | 221 |  |  |  | 99 |  |  |  | 503 |
Total share-based compensation expense |  | $ | (35 | ) |  | $ | 377 |  |  | $ | 997 |  |  | $ | 1,867 |
Related income tax benefit |  | $ | 67 |  |  | $ | 44 |  |  | $ | 192 |  |  | $ | 229 |
( 1 ) | During the three and nine months ended September 30, 2019, the Company reversed $0.5 million of previously recognized expense for certain performance awards after determining that the performance conditions are not expected to be met.
Stock options and SAR s The Company grants stock options and stock-settled SARs to employees that allow them to purchase shares of the Company’s common stock. Stock options are also granted to outside members of the Board of Directors of the Company. The Company determines the fair value of stock options and SARs at the date of grant using the Black-Scholes valuation model. All stock options and SARs granted prior to August 3, 2018 vested immediately when granted. Awards issued thereafter vest two years after the grant date. Employee awards expire five years after the grant date, and those issued to directors expire ten years after the grant date. The Company issues new shares upon the exercise of stock options and SARs. A summary of stock option transactions during the nine months ended September 30, 2019 follows:
|  |  |  |  |  |  |  |  |  | Weighted Average |  |  |  |  |
|  | No. of |  |  | Weighted Average |  |  | Remaining Life |  |  | Aggregate |
|  | Shares |  |  | Exercise Price |  |  | (in years) |  |  | Intrinsic Value |
Outstanding, January 1, 2019 |  |  | 676,846 |  |  | $ | 15.70 |  |  |  | 2.99 |  |  | $ | 2,230 |
Granted(1) |  |  | 184,994 |  |  |  | 17.22 |  |  |  |  |  |  |  |  |
Exercised |  |  | (75,444 | ) |  |  | 6.71 |  |  |  |  |  |  |  |  |
Cancelled |  |  | (80,005 | ) |  |  | 17.71 |  |  |  |  |  |  |  |  |
Outstanding, September 30, 2019 |  |  | 706,391 |  |  | $ | 16.83 |  |  |  | 3.20 |  |  | $ | 984 |
Options exercisable, September 30, 2019 |  |  | 497,993 |  |  | $ | 16.56 |  |  |  | 2.58 |  |  | $ | 967 |
( 1 ) | The weighted average grant date fair value of stock options granted was $3.96 per share.
As of September 30, 2019 , the Company had $0.4 million in unrecognized compensation related to nonvested stock options to be recognized over the remaining weighted average vesting period of 1.3 years. A summary of stock-settled SARs transactions during the nine months ended September 30, 2019 follows:
|  |  |  |  |  |  |  |  |  | Weighted Average |  |  |  |  |
|  | No. of |  |  | Weighted Average |  |  | Remaining Life |  |  | Aggregate |
|  | Shares |  |  | Exercise Price |  |  | (in years) |  |  | Intrinsic Value |
Outstanding, January 1, 2019 |  |  | 182,894 |  |  | $ | 18.99 |  |  |  | 2.61 |  |  | $ | 89 |
Granted(1) |  |  | 42,841 |  |  |  | 17.77 |  |  |  |  |  |  |  |  |
Exercised |  |  | - |  |  |  | - |  |  |  |  |  |  |  |  |
Cancelled |  |  | (19,035 | ) |  |  | 19.67 |  |  |  |  |  |  |  |  |
Outstanding, September 30, 2019 |  |  | 206,700 |  |  | $ | 18.67 |  |  |  | 2.29 |  |  | $ | - |
Options exercisable, September 30, 2019 |  |  | 168,478 |  |  | $ | 18.88 |  |  |  | 1.82 |  |  | $ | - |
( 1 ) | The weighted average grant date fair value of SARs granted was $3.97 per share.
As of September 30, 2019 , the Company had $0.1 million in unrecognized compensation related to nonvested SARs to be recognized over the remaining weighted average vesting period of 1.3 years. Restricted Stock The Company has granted restricted stock to directors and certain employees under the terms of the 2013 Plan which vest at a specified future date, generally after three years, or when certain conditions are met. The shares are subject to accelerated vesting under certain circumstances as outlined in the 2013 Plan. Expense for each of these grants is based on the fair value at the date of the grant and is being recognized on a straight-line basis over the respective service period. A summary of restricted stock transactions during the nine months ended September 30, 2019 follows:
|  |  |  |  |  | Weighted Average |
|  | No. of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Outstanding, January 1, 2019 |  |  | 92,032 |  |  | $ | 19.46 |
Granted |  |  | 48,829 |  |  |  | 17.41 |
Vested |  |  | - |  |  |  | - |
Cancelled |  |  | - |  |  |  | - |
Outstanding, September 30, 2019 |  |  | 140,861 |  |  | $ | 18.75 |
As of September 30, 2019 , the Company had $1.3 million of unrecognized compensation cost related to nonvested restricted stock grants expected to be recognized over the remaining weighted average vesting period of 1.6 years. Performance Shares Under the terms of the grants, certain employees received service-based or service-based and performance-based shares, to which we collectively refer to as performance shares. The service-based awards vest after the service period is met, which is generally three to five years. Expense for these grants is based on the fair value on the date of the grant and is being recognized on a straight-line basis over the respective service period. The performance-based shares generally vest after five years if the performance and service targets are met. The Company evaluates the performance conditions associated with these grants each reporting period to determine the expected number of shares to be issued. During the three and nine months ended September 30, 2019, the Company reversed $0.5 million of previously recognized expense for certain awards after determining that the performance conditions are not expected to be met. Expenses for grants of performance shares are recognized on a straight-line basis over the respective service period based on the grant date fair value and expected number of shares to be issued. The awards are subject to accelerated vesting under certain circumstances as outlined in the 2013 Plan. A summary of performance share transactions during the nine months ended September 30, 2019 follows:
|  |  |  |  |  | Weighted Average |
|  | No. of |  |  | Grant Date |
|  | Shares |  |  | Fair Value |
Outstanding, January 1, 2019 |  |  | 194,378 |  |  | $ | 20.08 |
Granted |  |  | 14,068 |  |  |  | 17.77 |
Vested |  |  | - |  |  |  | - |
Cancelled |  |  | (14,434 | ) |  |  | 22.03 |
Outstanding, September 30, 2019 |  |  | 194,012 |  |  | $ | 19.77 |
As of September 30, 2019 , the Company had $1.5 million of unrecognized compensation cost related to nonvested performance share grants expected to be recognized over the remaining weighted average service period of 2.1 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration